Global Retinal Vein Occlusion Market to Grow at a 16.04% CAGR of by 2018 Says a New Research Report at Sandlerresearch.org

Global Retinal Vein Occlusion Market 2014-2018 analyzes key players like Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc., Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, Texas (PRWEB) August 07, 2014

One of the growth-pertaining trends in the market is the introduction of biologics as a treatment option for retinal vein occlusion. Drugs such as Avastin (bevacizumab) and Lucentis (ranibizumab), which are Vascular Endothelial Growth Factor (VEGF) inhibitors, are being used in the treatment of retinal vein occlusion in patients. This is expected to drive the growth of the market in the forecast period.

Analysts forecast the Global Retinal Vein Occlusion market will grow at a CAGR of 16.04 percent over the period 2013-2018. According to the report, high unmet needs because of the presence of fewer approved treatment options for this indication are one of the major drivers of the market. There are only three drugs approved for the indication: Eylea, by Bayer and Regeneron Pharmaceuticals; Lucentis, by F. Hoffmann-La Roche and Novartis; and Ozurdex, by Allergan. Therefore, the launch of new products for the treatment of retinal vein occlusion is expected to drive the market.

Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.

This report covers the present scenario and the growth prospects of the Global Retinal Vein Occlusion market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of retinal vein occlusion.

Purchase Report @ http://www.sandlerresearch.org/purchase?rname=19831.

Global Retinal Vein Occlusion Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Retinal Vein Occlusion market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Global Retinal Vein Occlusion Market: Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc.

Other prominent vendors in the market are: Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals.

Further, the report states that one of the major challenges that the market faces is the serious adverse side effects associated with the drugs used to treat retinal vein occlusion. Some of the major side effects include increases in ocular pressure, glaucoma, conjunctival hemorrhage, cataract, headache, vitreous detachment, eye pain, endophthalmitis, eye redness, and specks in the vision. This lowers the acceptability of these drugs among patients and medical fraternities.

Key Regions

  •     Americas
  •     EMEA
  •     APAC

Key Market Driver

  •     High Unmet Need

Key Market Challenge

  •     Serious Adverse Side Effects

Key Market Trend

  •     Introduction of Biologics

Key Questions Answered in this Report

  •     What will the market size be in 2018 and what will the growth rate be?
  •     What are the key market trends?
  •     What is driving this market?
  •     What are the challenges to market growth?
  •     Who are the key vendors in this market space?
  •     What are the market opportunities and threats faced by the key vendors?
  •     What are the strengths and weaknesses of the key vendors?

Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Pipeline Portfolio
08. Rate of Incidence and Prevalence
09. Market Segmentation by Type of Therapy
10. Market Segmentation by Route of Administration
11. Market Segmentation by Dosage Forms
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
21. Key Vendor Analysis
22. Other Reports in this Series
21 Lists of Exhibits

Browse more reports on Pharmaceutical Market and Therapeutics Market.

About US
Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.


Contact

Follow us on: Contact's Google Plus

Past News Releases Group Rss Subscribe